The Chartis System* has been used in multiple randomized clinical trials1-4 to predict likely responders to the Zephyr Valve treatment. It provides precise flow and pressure readings for specific lobes in the lung to assess absence of collateral ventilation, which is a predictor of response to treatment.
Bluetooth® is a registered trademark owned by Bluetooth SIG, Inc.
*The Chartis System includes the Chartis Console and Catheter.
Overview of the Chartis Tablet features:
12.5″ wide viewing angle display. Full HD (1920 x 1080) graphics with “View Anywhere®” outdoor 1000 nit sunlight readable display
The tablet display can be moved or viewed independent of its base, which houses the interface with the Chartis catheter, to maximize utilization of space in the operating room and support simultaneous bronchoscope and Chartis visualization
Multiple Ventilation Modes
Works with spontaneous breathing or mechanical ventilation
Password Protected Log in and Secure Data Storage
Offers superior protection that can support hospital administration and PHI (protected health information) compliance considerations
Allows the tablet display to be positioned in easy view and reach
In patients who have been assessed by the Chartis System as having low collateral ventilation, treatment with Zephyr Endobronchial Valves lead to high responder rates and clinically significant improvement in symptoms compared to Standard of Care (SOC)1.
Chartis enables detection of collateral ventilation under different sedation methods
Chartis System Ordering Information*
|Chartis Pulmonary Assessment System – Console||CHR-CO-300|
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.